News Center
With the tenet of "Healthy China, Dedicated commitment", Linuo Pharmaceuticals increases cooperation and association with external scientific research institutes while innovating and developing independently.
04
2026
-
08
Double good news! Keyuan Pharmaceutical and Linuo Pharmaceutical have received approval for their supplemental drug applications.
Classification：
Corporate News
Double good news! Keyuan Pharmaceutical and Linuo Pharmaceutical have received approval for their supplemental drug applications.
Notice and Public Announcement of Proposed Winning Bids in the National Centralized Drug Procurement!
Recently, Shandong Linuo Pharmaceutical Co., Ltd., a wholly owned subsidiary of Shandong Keyuan Pharmaceutical Co., Ltd., received a Notice of Approval for a Supplemental Drug Application issued by the National Medical Products Administration. The specific details are as follows:
This approval will further broaden Lino Pharmaceutical’s product portfolio and refine its product lineup, thereby strengthening the company’s overall market competitiveness in relevant therapeutic areas. It is expected to deliver positive momentum to the company’s future operations and earnings growth, while reinforcing the foundation for the continued development of its core business.
The National Organization for Drug Centralized Procurement recently released the “Public Notice of Proposed Winning Bids for the 12th Batch of National Centralized Bulk Procurement of Drugs.” Lino Pharmaceutical’s products are proposed to be selected in this round of centralized procurement, with the relevant winning details as follows:
The enterprise currently slated to win the bid for Betahistine Hydrochloride Tablets is Senmiao (Shandong) Pharmaceutical Co., Ltd.; however, following the completion of the marketing authorization holder change, the designation will subsequently be updated to Linuo Pharmaceutical.
This round of centralized procurement represents the 12th batch of nationally organized drug centralized bulk purchasing coordinated by the Joint Procurement Office. During the procurement period, medical institutions will give priority to using the winning products from this round. Following the signing and implementation of procurement contracts, Linuo Pharmaceutical is expected to see rapid volume growth and market expansion for its winning products, enhance its brand visibility, and positively impact the company’s future financial performance.
For many years, Keyuan Pharmaceutical has remained committed to its original mission of “caring for life and health, and safeguarding a better future,” upholding the core values of “long-termism, product‑centricity, and altruism.” The company has steadily advanced an integrated strategy for both active pharmaceutical ingredients and finished dosage forms, ensuring the health and well‑being of the public with stable, reliable, high‑quality medicines. This double celebration not only marks a significant milestone in the company’s product pipeline development and market expansion but also serves as strong evidence of its continued dedication to the pharmaceutical industry and its proactive response to the national policy on centralized drug procurement.
Looking ahead, Keyuan Pharmaceutical, together with Linuo Pharmaceutical, will continue to expand its product portfolio, steadfastly uphold the highest standards of drug quality, proactively seize opportunities presented by centralized procurement policies, accelerate the market penetration and widespread availability of high‑quality finished dosage forms, and consistently enhance product accessibility and affordability, thereby striving to create greater value for both the company and society.
Related news
ADD：#30766 Jingshidong Road, Linuo High-tech Park, Jinan, Shandong Province, P. R. China